☆ 4.6 Editorial Material

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies

MOLECULAR CANCER THERAPEUTICS (2010)

Journal

MOLECULAR CANCER THERAPEUTICS

Volume 9, Issue 9, Pages 2447-2449

Publisher

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/1535-7163.MCT-10-0719

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies

David Zahavi, James W. W. Hodge

Summary: The tumor microenvironment plays a crucial role in regulating cancer progression and the immune response. Cancer cells utilize various immunosuppressive mechanisms to weaken immune cell function in the tumor microenvironment. Targeting the adenosine signaling pathway represents a promising immunotherapeutic strategy that can potentially enhance the effectiveness of conventional anti-cancer treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and Chemoresistance

Mariam Ahmed Galal, Samhar Samer Alouch, Buthainah Saad Alsultan, Huda Dahman, Nouf Abdullah Alyabis, Sarah Ammar Alammar, Ahmad Aljada

Summary: This comprehensive review thoroughly explores the intricate involvement of insulin receptor isoforms and insulin-like growth factor receptors in the insulin and insulin-like growth factor signaling pathway, emphasizing their crucial roles in cancer development and resistance to anti-cancer drugs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting strategies for bone diseases: signaling pathways and clinical studies

Hao Xu, Wentao Wang, Xin Liu, Wei Huang, Chen Zhu, Yaozeng Xu, Huilin Yang, Jiaxiang Bai, Dechun Geng

Summary: Since the proposal of Paul Ehrlich's magic bullet concept over 100 years ago, tremendous advances have occurred in targeted therapy. Bone-targeted therapy has been considered a promising therapeutic approach for handling the challenges in drug therapy for skeletal diseases. Recent advances in therapeutic strategies based on bone targeting, including targeting strategies based on bone structure and remodeling biology, as well as bone-targeted therapeutic agents and drug delivery strategies, are discussed in this review.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Add to Collection

Review Endocrinology & Metabolism

Insulin-like growth factors: Ligands, binding proteins, and receptors

Derek LeRoith, Jeff M. P. Holly, Briony E. Forbes

Summary: The IGF family of ligands, receptors, and binding proteins play critical roles in normal human physiology and disease states. IGF-I regulates cellular growth, differentiation, and survival to control overall body growth, while IGF-II has important effects prenatally and in tissue-specific roles in adults.

MOLECULAR METABOLISM (2021)

Add to Collection

Review Endocrinology & Metabolism

Controlled Signaling-Insulin-Like Growth Factor Receptor Endocytosis and Presence at Intracellular Compartments

Leonie Rieger, Rosemary O'Connor

Summary: The internalization and localization of the IGF-1 receptor play crucial roles in cell signaling and biological processes, with different cell types and cell adhesion receptors regulating this process. Further study on how IGF-1R intracellular trafficking and compartmentalized signaling is controlled, particularly in cancer, is needed.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity

Mahmoud Abdellatif, Viktoria Trummer-Herbst, Alexander Martin Heberle, Alina Humnig, Tobias Pendl, Sylvere Durand, Giulia Cerrato, Sebastian J. Hofer, Moydul Islam, Julia Voglhuber, Jose Miguel Ramos Pittol, Oliver Kepp, Gerald Hoefler, Albrecht Schmidt, Peter P. Rainer, Daniel Scherr, Dirk von Lewinski, Egbert Bisping, Julie R. McMullen, Abhinav Diwan, Tobias Eisenberg, Frank Madeo, Kathrin Thedieck, Guido Kroemer, Simon Sedej

Summary: This study suggests a biphasic relationship between insulin-like growth factor 1 receptor (IGF1R) signaling and cardiac health. Higher IGF1R signaling in young mice leads to declining cardiac function and shorter lifespan, while lower IGF1R signaling improves cardiac function and extends lifespan in aging mice.

CIRCULATION (2022)

Add to Collection

Article Entomology

Functional evaluation of the insulin/insulin-like growth factor signaling pathway in determination of wing polyphenism in pea aphid

Yiyang Yuan, Yanyan Wang, Wanwan Ye, Erliang Yuan, Jian Di, Xin Chen, Yanling Xing, Yucheng Sun, Feng Ge

Summary: This study investigates the role of the insulin/insulin-like growth factor signaling (IIS) pathway in regulating transgenerational wing polyphenism in aphids. It is found that ILP5 and FoxO play important roles in controlling wing morph development in embryos. ILP4 and ILP11 are also associated with wing polyphenism, but the regulation may not involve the canonical IIS pathway.

INSECT SCIENCE (2023)

Add to Collection

Review Chemistry, Medicinal

The effects of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding proteins: A systematic review of randomized controlled trials

Fatemeh Meshkini, Nahid Ramezani-Jolfaie, Saman Sargazi, Cain C. T. Clark, Sepideh Soltani

Summary: A systematic review of the effects of lycopene on circulating IGF-1 and IGFBPs in adults found no consistent modifying effect of lycopene supplementation on IGF-1 and IGFBP levels. More research is needed to explore the effect of lycopene on the IGF-1 system.

PHYTOTHERAPY RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Tangeretin promotes lifespan associated with insulin/insulin-like growth factor-1 signaling pathway and heat resistance in Caenorhabditis elegans

Yalei Liu, Zhenyu Zhou, Liufang Yin, Mengnan Zhu, Fei Wang, Lijun Zhang, Hongqing Wang, Zhiqin Zhou, Huanhu Zhu, Cheng Huang, Shengjie Fan

Summary: Tangeretin, a polymethoxylated flavonoid found in citrus fruits, has shown significant antiaging effects by extending the mean lifespan, slowing down aging-related functional declines, and enhancing heat stress tolerance in Caenorhabditis elegans. Its effects are dependent on the insulin/insulin-like growth factor signaling pathway.

BIOFACTORS (2022)

Add to Collection

Review Endocrinology & Metabolism

Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential

Armel H. H. Nwabo Kamdje, Paul F. Seke Etet, Maulilio J. Kipanyula, Lorella Vecchio, Richard Tagne Simo, Alfred K. Njamnshi, Kiven E. Lukong, Patrice N. Mimche

Summary: The tumor microenvironment plays a role in tumorigenesis and drug resistance through the overexpression of insulin-like growth factor 1 (IGF-1). Anti-IGF therapies have shown potential in inhibiting cancer and overcoming chemotherapy drug resistance in preclinical studies, but toxicity and resistance are challenges in clinical trials.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

IGFBP-3 promotes cachexia-associated lipid loss by suppressing insulin-like growth factor/insulin signaling

Xiaohui Wang, Jia Li, Wei Zhang, Feng Wang, Yunzi Wu, Yulin Guo, Dong Wang, Xinfeng Yu, Ang Li, Fei Li, Yibin Xie

Summary: This study reveals that tumor-derived IGFBP-3 plays a critical role in cancer-associated cachexia by causing lipid loss in mature adipocytes. IGFBP-3 antagonizes insulin/IGF-like signaling and impairs the balance between lipolysis and lipogenesis. The findings suggest that tumor-derived IGFBP-3 may serve as a biomarker for the diagnosis of cachexia in cancer patients.

CHINESE MEDICAL JOURNAL (2023)

Add to Collection

Article Medicine, Research & Experimental

Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor

Ho Jin Lee, Phuong Chi Pham, Honglan Pei, Bumhee Lim, Seung Yeob Hyun, Byungyeob Baek, Byungjin Kim, Yunha Kim, Min-Hwan Kim, Nae-Won Kang, Hye-Young Min, Dae-Duk Kim, Jeeyeon Lee, Ho-Young Lee

Summary: The study revealed that LL6 is a novel IGF-1R/Src/AXL-targeting small molecule kinase inhibitor, showing inhibitory effects on non-small cell lung cancer cells, reducing tumor growth and metastasis with low toxicity.

THERANOSTICS (2021)

Add to Collection

Review Endocrinology & Metabolism

The Origination of Growth Hormone/Insulin-Like Growth Factor System: A Story From Ancient Basal Chordate Amphioxus

Mengyang Li

Summary: The GH/IGF system plays a role in growth regulation in the body. By studying the basal chordate amphioxus, it was discovered that most members of the GH/IGF system are present in amphioxus, providing strong evidence for the origin of this system in amphioxus.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Food Science & Technology

Kahweol, a coffee diterpene, increases lifespan via insulin/insulin-like growth factor-1 and AMP-activated protein kinase signaling pathways in Caenorhabditis elegans

Junhyo Cho, Yeonhwa Park

Summary: Coffee's kahweol compound has been found to extend the lifespan of C. elegans, independent of reduced food intake. It acts through the insulin/insulin-like growth factor-1 signaling pathway and may involve the AMPK pathway.

CURRENT RESEARCH IN FOOD SCIENCE (2023)

Add to Collection

Review Neurosciences

Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders

Rashita Makkar, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Hafiz A. Makeen, Mohammed Albratty, Hassan A. Alhazmi, Aldulkarim M. Meraya

Summary: The degradation of neurons is the pathological reason for onset of most neurological diseases. IGF-I can promote neuronal regeneration and has neuroprotective properties. Studying the signaling pathways of IGF-I is significant for the treatment and management of neurological disorders.

NEUROTOXICITY RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

Emma Scott, Kirsty Hodgson, Beatriz Calle, Helen Turner, Kathleen Cheung, Abel Bermudez, Fernando Jose Garcia Marques, Hayley Pye, Edward Christopher Yo, Khirul Islam, Htoo Zarni Oo, Urszula L. McClurg, Laura Wilson, Huw Thomas, Fiona M. Frame, Margarita Orozco-Moreno, Kayla Bastian, Hector M. Arredondo, Chloe Roustan, Melissa Anne Gray, Lois Kelly, Aaron Tolson, Ellie Mellor, Gerald Hysenaj, Emily Archer Goode, Rebecca Garnham, Adam Duxfield, Susan Heavey, Urszula Stopka-Farooqui, Aiman Haider, Alex Freeman, Saurabh Singh, Edward W. Johnston, Shonit Punwani, Bridget Knight, Paul McCullagh, John McGrath, Malcolm Crundwell, Lorna Harries, Denisa Bogdan, Daniel Westaby, Gemma Fowler, Penny Flohr, Wei Yuan, Adam Sharp, Johann de Bono, Norman J. Maitland, Simon Wisnovsky, Carolyn R. Bertozzi, Rakesh Heer, Ramon Hurtado Guerrero, Mads Daugaard, Janne Leivo, Hayley Whitaker, Sharon Pitteri, Ning Wang, David J. Elliott, Benjamin Schumann, Jennifer Munkley

Summary: Prostate cancer is the leading cancer among men, causing over 350,000 deaths worldwide annually. This study reveals that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue and can be used as a biomarker to diagnose the disease with higher accuracy than the traditional PSA test. Additionally, GALNT7 is found to play a role in promoting prostate tumor growth and is associated with cell cycle and immune signaling pathways. Overall, this study highlights the importance of GALNT7-mediated O-glycosylation in prostate cancer progression.

ONCOGENE (2023)

Add to Collection

Article Oncology

Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer

Nicolo Bancaro, Bianca Cali, Martina Troiani, Angela Rita Elia, Rydell Alvarez Arzola, Giuseppe Attanasio, Ping Lai, Mateus Crespo, Bora Gurel, Rita Pereira, Christina Guo, Simone Mosole, Daniela Brina, Mariantonietta D'Ambrosio, Emiliano Pasquini, Clarissa Spataro, Elena Zagato, Andrea Rinaldi, Mattia Pedotti, Simona Di Lascio, Francesco Meani, Monica Montopoli, Matteo Ferrari, Andrea Gallina, Luca Varani, Ricardo Pereira Mestre, Marco Bolis, Silke Gillessen Sommer, Johann de Bono, Arianna Calcinotto, Andrea Alimonti

Summary: Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. We have identified a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment. These senescent-like neutrophils express TREM2 and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils.

CANCER CELL (2023)

Add to Collection

Article Oncology

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin

Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Correction Urology & Nephrology

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer (vol 83, pg 224, 2023)

Christina Guo, Ines Figueiredo, Bora Gurel, Antje Neeb, George Seed, Mateus Crespo, Suzanne Carreira, Jan Rekowski, Lorenzo Buroni, Jon Welti, Denisa Bogdan, Lewis Gallagher, Adam Sharp, Maria D. Fenor de la Maza, Pasquale Rescigno, Daniel Westaby, Khobe Chandran, Ruth Riisnaes, Ana Ferreira, Susana Miranda, Bianca Cali, Andrea Alimanti, Silvia Bressan, Alana H. T. Nguyen, Michael M. Shen, Jessica E. Hawley, Aleksandar Obradovic, Charles G. Drake, Claudia Bertan, Chloe Baker, Nina Tunariu, Wei Yuan, Johann S. de Bono

EUROPEAN UROLOGY (2023)

Add to Collection

Article Oncology

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly

Summary: This study validated a prognostic model of overall survival in men with metastatic, castration-resistant prostate cancer treated with docetaxel. The model accurately predicts the survival of patients and performs well across different racial, age, and treatment subgroups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study

Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap

Summary: This study aims to develop guidelines for early phase dose-finding trials through reviewing published trial reports and conducting a Delphi process. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines were developed, and a lay summary toolkit was created through patient and public involvement.

BMC MEDICINE (2023)

Add to Collection

Article Oncology

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono

Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Biochemical Research Methods

Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines

Rachel Lau, Lu Yu, Theodoros I. Roumeliotis, Adam Stewart, Lisa Pickard, Ruth Riisanes, Bora Gurel, Johann S. de Bono, Jyoti S. Choudhary, Udai Banerji

Summary: This study aimed to profile the proteome of cancer-associated fibroblasts (CAFs) and identify novel CAF biomarkers. The proteomic analysis revealed the upregulation of N-glycan biosynthesis and extracellular matrix proteins in CAFs, as well as the overexpression of heat shock protein & beta;-6 (HSPB6/HSP20) and cyclooxygenase 1 (PTGS1/COX1) as novel CAF biomarkers. Immunohistochemical analysis showed restricted expression of HSPB6 and PTGS1 in the stroma of tumor samples.

JOURNAL OF PROTEOMICS (2023)

Add to Collection

Article Medicine, Research & Experimental

Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

Antje Neeb, Ines Figueiredo, Bora Gurel, Daniel Nava Rodrigues, Jan Rekowski, Ruth Riisnaes, Ana Ferreira, Susana Miranda, Mateus Crespo, Daniel Westaby, Maria de Los Dolores Fenor de La Maza, Christina Guo, Juliet Carmichael, Rafael Grochot, Nina Tunariu, Andrew C. B. Cato, Stephen R. Plymate, Johann S. de Bono, Adam Sharp

Summary: BAG-1L protein plays a critical role in the development and progression of prostate cancer. This study developed a new BAG-1L-specific antibody and explored its expression in different types of prostate cancer and breast cancer tissues. The results showed higher BAG-1L protein expression in castration-resistant prostate cancer metastases, indicating a possible association with more aggressive biology and the development of castration resistance.

LABORATORY INVESTIGATION (2023)

Add to Collection

Article Medicine, General & Internal

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J. Weir

Summary: The CONSORT-DEFINE guidance provides comprehensive reporting guidelines for early phase dose-finding trials, aiming to improve the quality of reporting and facilitate result interpretation.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Add to Collection

Article Medicine, General & Internal

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance

Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J. Weir, An-Wen Chan, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Melanie Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P. Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Johann de Bono

Summary: SPIRIT 2013 provides guidance for clinical trial protocol writing but doesn't cover early phase dose-finding trials adequately. The DEFINE statement is a new guideline that includes recommendations for essential items in the protocols of these trials.

BMJ-BRITISH MEDICAL JOURNAL (2023)

Add to Collection

Article Oncology

The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells

Daniela Brina, Adele Ponzoni, Martina Troiani, Bianca Cali, Emiliano Pasquini, Giuseppe Attanasio, Simone Mosole, Michela Mirenda, Mariantonietta D'Ambrosio, Manuel Colucci, Ilaria Guccini, Ajinkya Revandkar, Abdullah Alajati, Toma Tebaldi, Deborah Donzel, Fabio Lauria, Nahjme Parhizgari, Aurora Valdata, Martino Maddalena, Arianna Calcinotto, Marco Bolis, Andrea Rinaldi, Simon Barry, Jan Hendrik Rueschoff, Marianna Sabbadin, Semini Sumanasuriya, Mateus Crespo, Adam Sharp, Wei Yuan, Mathew Grinu, Alexandra Boyle, Cynthia Miller, Lloyd Trotman, Nicolas Delaleu, Matteo Fassan, Holger Moch, Gabriella Viero, Johann de Bono, Andrea Alimonti

Summary: In prostate cancer, the secretome is rewired at the translational level to recruit MDSCs, with Hgf, Spp1, and Bgn identified as key regulators. By inhibiting the MNK/eIF4E and AKT pathways, this study provides a therapeutic strategy that combines translation inhibition with immunotherapy to restore immune surveillance in prostate cancer.

NATURE CANCER (2023)

Add to Collection

Article Oncology

Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Karim Fizazi, Ken Herrmann, Bernd J. Krause, Kambiz Rahbar, Kim N. Chi, Michael J. Morris, Oliver Sartor, Scott T. Tagawa, Ayse T. Kendi, Nicholas Vogelzang, Jeremie Calais, James Nagarajah, Xiao X. Wei, Vadim S. Koshkin, Jean-Mathieu Beauregard, Brian Chang, Ray Ghouse, Michelle DeSilvio, Richard A. Messmann, Johann de Bono

Summary: In the VISION study, lutetium-177 (177Lu) Lu-PSMA-617 improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Additional results showed improvements in health-related quality of life, pain, and symptomatic skeletal events.

LANCET ONCOLOGY (2023)

Add to Collection

Article Urology & Nephrology

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer

Rafael Grochot, Suzanne Carreira, Susana Miranda, Ines Figueiredo, Claudia Bertan, Jan Rekowski, Wei Yuan, Ana Ferreira, Ruth Riisnaes, Antje Neeb, Bora Gurel, Maria de Los Dolores Fenor de la Maza, Christina Guo, Juliet Carmichael, Daniel Westaby, Joaquin Mateo, Adam Sharp, Terri P. McVeigh, Johann De Bono

Summary: This study investigated the clinical and pathological features of advanced prostate cancer associated with germline mutations in the ATM gene. It was found that most of these patients had a high family history of cancer, and this mutation may predict the progression of these prostate cancers and response to specific treatments.

EUROPEAN UROLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Targeting CBP/p300 and its downstream transcriptional machinery in advanced PCa

Sumaira Sardar, Lakshmi Ravindranath, Christopher McNair, Saswati Chand, Wei Yuan, Denisa Bogdan, Jon Welti, Adam Sharp, Matthew Schiewer, Lisa Butler, Johann DeBono, Kris Frese, Nigel Brooks, Neil Pegg, Karen Knudsen

CANCER RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.